Tanya joined Sitryx as CBO in October 2021, and brings 15 years of experience in Business Development, Business Insights, and Corporate Strategy across the global biotech and pharmaceutical communities. She most recently held the role of Vice President of Pipeline Strategy and Alliances at Flagship Pioneering, where she helped guide business development and strategic pipeline creation across numerous technology platforms and therapeutic areas for early-stage companies in the Flagship ecosystem. Prior to this, she was co-founder and Director of the Business Development Search and Evaluation team at Celgene Corporation, later acquired by Bristol Myers Squibb, where she helped lead BD activities in Oncology, Hematology and Cell Therapy. Previously, Tanya was responsible for Global Market Insights strategy across the entire Celgene Oncology/Hematology portfolio, and U.S Business Insights for Halaven at Eisai Pharmaceuticals. She began her career in Management Consulting at Easton Associates LLC, a boutique strategic management consulting firm focused on the Biotech and Pharma industries based in New York City.
Tanya holds a Doctorate in Cell Biology and Molecular Genetics from Rutgers University in New Jersey, a bachelor’s degree in Biology from Queen’s University at Kingston, Ontario, Canada, and a Mini-MBA from the Rutgers University Business School.